Antigen-binding proteins that activate the leptin receptor
The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.
1. A method for treating a disease or condition associated with or caused by leptin deficiency or leptin resistance, the method comprising administering a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof that binds human leptin receptor (LEPR) and activates LEPR signaling, and a pharmaceutically acceptable carrier or diluent to a subject in need thereof, wherein the antibody or antigen-binding fragment thereof comprises:
a light chain variable region that comprises the complementarity determining regions (CDRs) of a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 10; and
a heavy chain variable region that comprises the CDRs of a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 26 or SEQ ID NO: 34.
2. The method of claim 1 wherein the antibody or antigen-binding fragment comprises
a heavy chain variable region that comprises
a HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 4,
a HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 6, and
a HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 8; and
a light chain variable region that comprises
a LCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 12,
a LCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 14, and
a LCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 16.
3. The method of claim 1 wherein the antibody or antigen-binding fragment comprises
a heavy chain variable region that comprises
a HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 36,
a HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 38, and
a HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 40; and
a light chain variable region that comprises
a LCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 12,
a LCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 14, and
a LCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 16.
4. The method of claim 1 wherein the antibody or antigen-binding fragment comprises
a heavy chain variable region that comprises
a HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 28,
a HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 30, and
a HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 32; and
a light chain variable region that comprises
a LCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 12,
a LCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 14, and
a LCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 16.
5. The method of claim 2 wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 10; and a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 2.
6. The method of claim 5 wherein the antibody or antigen-binding fragment thereof is an antibody.
7. The method of claim 6 wherein the antibody comprises
a heavy chain variable region that is linked to a human IgG1 heavy chain constant domain; and
a light chain variable region that is linked to a human kappa light chain constant domain.
8. The method of claim 6 wherein the antibody comprises
a heavy chain variable region that is linked to a human IgG4 heavy chain constant domain; and
a light chain variable region that is linked to a human kappa light chain constant domain.
9. The method of claim 3 wherein the antibody or antigen-binding fragment thereof comprises
a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 10; and
a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 34.
10. The method of claim 9 wherein the antibody or antigen-binding fragment thereof is an antibody.
11. The method of claim 10 wherein the antibody comprises
a heavy chain variable region that is linked to a human IgG1 heavy chain constant domain; and
a light chain variable region that is linked to a human kappa light chain constant domain.
12. The method of claim 10 wherein the antibody comprises
a heavy chain variable region that is linked to a human IgG4 heavy chain constant domain; and
a light chain variable region that is linked to a human kappa light chain constant domain.
13. The method of claim 4 wherein the antibody or antigen-binding fragment thereof comprises
a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 10; and
a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 26.
14. The method of claim 13 wherein the antibody or antigen-binding fragment thereof is an antibody.
15. The method of claim 14 wherein the antibody comprises
a heavy chain variable region that is linked to a human IgG1 heavy chain constant domain; and
a light chain variable region that is linked to a human kappa light chain constant domain.
16. The method of claim 14 wherein the antibody comprises
a heavy chain variable region that is linked to a human IgG4 heavy chain constant domain; and
a light chain variable region that is linked to a human kappa light chain constant domain.
17. The method of claim 14 wherein the disease or condition associated with or caused by leptin deficiency or leptin resistance is lipodystrophy.
18. The method of claim 14 wherein the disease or condition associated with or caused by leptin deficiency or leptin resistance is generalized lipodystrophy.
19. The method of claim 14 wherein the disease or condition associated with or caused by leptin deficiency or leptin resistance is congenital generalized lipodystrophy.
20. The method of claim 14 wherein the disease or condition associated with or caused by leptin deficiency or leptin resistance is acquired generalized lipodystrophy.
21. The method of claim 17 wherein the pharmaceutical composition is delivered to the subject subcutaneously.
22. The method of claim 18 wherein the pharmaceutical composition is delivered to the subject subcutaneously.
23. The method of claim 19 wherein the pharmaceutical composition is delivered to the subject subcutaneously.
24. The method of claim 20 wherein the pharmaceutical composition is delivered to the subject subcutaneously.
25. The method of claim 14 , wherein the disease or condition associated with or caused by leptin deficiency or leptin resistance is selected from the group consisting of diet-induced food craving, functional hypothalamic amenorrhea, Alzheimer's disease, Leprechaunism/Donohue syndrome, and Rabson-Mendenhall syndrome.
26. The method of claim 14 , wherein the disease or condition associated with or caused by leptin deficiency or leptin resistance is type 1 diabetes.
27. The method of claim 14 , wherein the disease or condition associated with or caused by leptin deficiency or leptin resistance is type 2 diabetes.
28. The method of claim 14 , wherein the disease or condition associated with or caused by leptin deficiency or leptin resistance is insulin resistance.
29. The method of claim 14 , wherein the disease or condition associated with or caused by leptin deficiency or leptin resistance is severe insulin resistance due to mutation in the insulin receptor.
30. The method of claim 14 , wherein the disease or condition associated with or caused by leptin deficiency or leptin resistance is obesity.
31. The method of claim 14 , wherein the disease or condition associated with or caused by leptin deficiency or leptin resistance is metabolic syndrome.
32. The method of claim 14 , further comprising administering a second therapeutic agent to the subject.
33. The method of claim 14 , further comprising administering a second therapeutic agent to the subject, wherein the second therapeutic agent is selected from the group consisting of a recombinant human leptin, a PCSK9 inhibitor, a statin, ezetimibe, insulin, an insulin variant, an insulin secretagogue, metformin, a sulfonylurea, a sodium glucose cotransporter 2 (SGLT2) inhibitor, a GLP-1 agonist/analogue, a glucagon (GCG) inhibitor, a glucagon receptor (GCGR) inhibitor, an angiopoietin-like protein (ANGPTL) inhibitor, phentermine, orlistat, topiramate, bupropion, topiramate and phentermine, bupropion and naltrexone, bupropion and zonisamide, pramlintide and metrelepin, lorcaserin, cetilistat, tesofensine, and velneperit.
34. The method of claim 30 wherein the pharmaceutical composition is delivered to the subject subcutaneously.